Zacks Investment Research downgraded shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a buy rating to a hold rating in a research report report published on Friday.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
AEZS has been the subject of a number of other research reports. Maxim Group set a $4.00 target price on shares of AEterna Zentaris and gave the company a buy rating in a research report on Wednesday, March 28th. ValuEngine lowered shares of AEterna Zentaris from a sell rating to a strong sell rating in a research report on Thursday, March 1st. Finally, HC Wainwright reiterated a buy rating and issued a $3.00 target price on shares of AEterna Zentaris in a research report on Thursday, March 29th.
Shares of AEZS opened at $1.35 on Friday. The stock has a market capitalization of $22.20, a P/E ratio of -1.00 and a beta of 0.92. AEterna Zentaris has a 52-week low of $0.78 and a 52-week high of $3.75.
A hedge fund recently raised its stake in AEterna Zentaris stock. JPMorgan Chase & Co. boosted its stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,800 shares of the biopharmaceutical company’s stock after buying an additional 46,500 shares during the period. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 at the end of the most recent quarter. 1.91% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/zacks-investment-research-lowers-aeterna-zentaris-aezs-to-hold.html.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency.
Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.